

## PHARMACY POLICY STATEMENT

North Carolina Marketplace

**DRUG NAME** 

Phosphodiesterase Type 5 Inhibitors (PDE -5 Inhibitors) for Pulmonary Arterial



## Appendix:

## World Health Organization Functional Assessment Classification

Class I Patients with PAH but without resulting limitation of physical activity.

Ordinary physical activity does not cause undue dyspnea, fatigue, chest pain or near syncope.

Class II